NCT02181556View on ClinicalTrials.gov

Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

July 31, 2017

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

FOLFIRI Protocol

injection of FOLFIRI and Aflibercept every 14 days until progression of disease

DRUG

Aflibercept Injection

injection of FOLFIRI and Aflibercept every 14 days until progression of disease

Trial Locations (8)

13000

La Timone, Marseille

21079

CHU - Hôpital François Mitterand, Dijon

37044

Hôpital Trousseau, Tours

75020

Hôpital Européen Geaorge Pompidou (HEGP), Paris

93000

Hôpital Avicenne, Bobigny

Unknown

CHU - Hôtel Dieu, Angers

Clinique Jean Mermoz, Lyon

Hôpital La Pitié Salpetière, Paris

All Listed Sponsors
lead

Federation Francophone de Cancerologie Digestive

OTHER

NCT02181556 - Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter